AU2017291321B2 - Compositions and methods for modulating IL-10 immunostimulatory and anti-inflammatory properties - Google Patents

Compositions and methods for modulating IL-10 immunostimulatory and anti-inflammatory properties Download PDF

Info

Publication number
AU2017291321B2
AU2017291321B2 AU2017291321A AU2017291321A AU2017291321B2 AU 2017291321 B2 AU2017291321 B2 AU 2017291321B2 AU 2017291321 A AU2017291321 A AU 2017291321A AU 2017291321 A AU2017291321 A AU 2017291321A AU 2017291321 B2 AU2017291321 B2 AU 2017291321B2
Authority
AU
Australia
Prior art keywords
polypeptide
amino acid
linker
scil
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017291321A
Other languages
English (en)
Other versions
AU2017291321A1 (en
Inventor
Juan C. Alvarez
Heather C. Losey
Demetri T. Moustakas
Mark N. Namchuk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkermes Inc
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Inc filed Critical Alkermes Inc
Publication of AU2017291321A1 publication Critical patent/AU2017291321A1/en
Application granted granted Critical
Publication of AU2017291321B2 publication Critical patent/AU2017291321B2/en
Priority to AU2020204457A priority Critical patent/AU2020204457A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2017291321A 2016-06-22 2017-06-22 Compositions and methods for modulating IL-10 immunostimulatory and anti-inflammatory properties Ceased AU2017291321B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020204457A AU2020204457A1 (en) 2016-06-22 2020-07-03 Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662353478P 2016-06-22 2016-06-22
US62/353,478 2016-06-22
PCT/US2017/038747 WO2018005226A2 (en) 2016-06-22 2017-06-22 Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020204457A Division AU2020204457A1 (en) 2016-06-22 2020-07-03 Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties

Publications (2)

Publication Number Publication Date
AU2017291321A1 AU2017291321A1 (en) 2018-12-13
AU2017291321B2 true AU2017291321B2 (en) 2020-06-18

Family

ID=60674961

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017291321A Ceased AU2017291321B2 (en) 2016-06-22 2017-06-22 Compositions and methods for modulating IL-10 immunostimulatory and anti-inflammatory properties
AU2020204457A Abandoned AU2020204457A1 (en) 2016-06-22 2020-07-03 Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020204457A Abandoned AU2020204457A1 (en) 2016-06-22 2020-07-03 Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties

Country Status (6)

Country Link
US (2) US10335459B2 (https=)
EP (1) EP3474884A4 (https=)
JP (1) JP7084881B2 (https=)
AU (2) AU2017291321B2 (https=)
CA (1) CA3026393C (https=)
WO (1) WO2018005226A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
RU2593715C2 (ru) 2010-09-15 2016-08-10 Рэндэлл Дж. МРСНИ Системы и способы доставки биоактивных средств с применением транспортных последовательностей, происходящих от бактериального токсина
CN106470707A (zh) 2014-05-07 2017-03-01 应用分子运输有限责任公司 用于口服递送生物活性货物的cholix毒素衍生的融合分子
AU2015364396B2 (en) * 2014-12-19 2018-08-09 Alkermes, Inc. Single chain Fc fusion proteins
WO2018005226A2 (en) 2016-06-22 2018-01-04 Alkermes, Inc. Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
AU2019240370B2 (en) * 2018-03-23 2024-03-07 Gavish-Galilee Bio Applications Ltd. Genetically reprogrammed Tregs expressing membrane-bound IL-10
EP4083058A3 (en) 2018-11-07 2023-01-11 Applied Molecular Transport Inc. Delivery constructs for transcytosis and related methods
EP3927728A2 (en) * 2019-02-21 2021-12-29 Xencor, Inc. Untargeted and targeted il-10 fc-fusion proteins
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.
EP3795583A1 (en) * 2019-09-19 2021-03-24 Ecole Polytechnique Federale de Lausanne (EPFL) Il10/fc fusion proteins useful as enhancers of immunotherapies
CN112625137B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白及其医药用途
FI4065585T3 (fi) 2019-11-25 2025-09-26 Alkermes Inc Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä
EP4126017A4 (en) * 2020-04-03 2024-05-22 Baylor College of Medicine Tnf-alpha signaling triggers tumor-promoting inflammation that can be targeted to therapy
WO2021231447A1 (en) 2020-05-12 2021-11-18 Regeneron Pharmaceuticals, Inc. Novel il10 agonists and methods of use thereof
CA3180304A1 (en) * 2020-05-28 2021-12-02 Kenan Christopher GARCIA Engineered interleukin-10 polypeptides and uses thereof
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
EP4612165A1 (en) * 2022-11-02 2025-09-10 Synerkine Pharma B.V. Engineered immunocytokines, fusion polypeptides, and il10 polypeptides
CN118221829A (zh) * 2022-12-21 2024-06-21 广东菲鹏制药股份有限公司 一种il-10单体融合蛋白
WO2024144336A1 (ko) * 2022-12-30 2024-07-04 주식회사 프로젠 신규 이중 특이성 융합단백질 및 그의 용도
EP4719457A2 (en) * 2023-06-02 2026-04-08 Synthekine, Inc. Fused il10 polypeptides
WO2025247362A1 (zh) * 2024-05-31 2025-12-04 江苏先声生物制药有限公司 抗cdh17抗体、缀合物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6428985B1 (en) * 1998-12-02 2002-08-06 The Regents Of The University Of Michigan Immunosuppressive structural definition of IL-10
US20130316404A1 (en) * 2010-11-26 2013-11-28 The University Of Manchester Covalently linked interleukin-10
US20130336925A1 (en) * 2012-06-08 2013-12-19 Alkermes, Inc. Fusion Polypeptides Comprising Mucin-Domain Polypeptide Linkers
WO2015017548A2 (en) * 2013-07-31 2015-02-05 Amgen Inc. Stabilization of fc-containing polypeptides
WO2016100788A1 (en) * 2014-12-19 2016-06-23 Alkermes, Inc. Single chain fc fusion proteins

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0939121B2 (de) 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
WO2000029447A1 (en) 1998-11-19 2000-05-25 Smithkline Beecham Corporation Rhamm antagonist antibodies
US7754855B1 (en) 1999-07-13 2010-07-13 Bolder Biotechnology, Inc. Immunoglobulin fusion proteins
WO2001058950A1 (en) * 2000-02-11 2001-08-16 Maxygen Aps Improved interleukin 10
AU2003280315A1 (en) * 2002-11-14 2004-06-03 Maxygen, Inc. Conjugates of interleukin-10 and polymers
PL2298347T3 (pl) 2003-05-06 2016-03-31 Bioverativ Therapeutics Inc Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
US7696322B2 (en) 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
US20150071948A1 (en) 2003-09-26 2015-03-12 Gregory Alan Lazar Novel immunoglobulin variants
WO2008140595A2 (en) 2006-12-01 2008-11-20 President And Fellows Of Harvard College Synthetic trivalent haptens, complexes thereof, and uses therefor
BR112012017164A2 (pt) 2009-12-22 2019-09-24 Novartis Ag proteína de fusão de região constante de anticorpo-cd47 tetravalente
CA2785907A1 (en) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
BR112012028893A2 (pt) 2010-05-10 2017-12-12 Ascend Biopharmaceuticals Pty Ltd composições imunoestimuladoras e de vacina
CN101962413B (zh) * 2010-09-21 2013-03-13 中国科学技术大学 具有透皮能力和白细胞介素-10活性的融合蛋白及其编码基因与应用
US8883134B2 (en) 2010-10-20 2014-11-11 Handok Pharmaceuticals, Inc. Human interleukin-1 receptor antagonist—hybrid Fc fusion protein
TWI743461B (zh) 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP2723380B1 (en) 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
NO2748201T3 (https=) 2011-08-23 2018-05-12
US9062120B2 (en) 2012-05-02 2015-06-23 Janssen Biotech, Inc. Binding proteins having tethered light chains
IN2015DN01299A (https=) 2012-07-23 2015-07-03 Zymeworks Inc
PE20150645A1 (es) * 2012-08-08 2015-05-11 Roche Glycart Ag Proteinas de fusion de interleuquina 10 y usos de las mismas
US11634502B2 (en) 2013-03-15 2023-04-25 Amgen Inc. Heterodimeric bispecific antibodies
EP2989240A4 (en) 2013-04-24 2016-10-19 Armo Biosciences Inc INTERLEUKIN-10 COMPOSITIONS AND USES THEREOF
WO2015117930A1 (en) 2014-02-06 2015-08-13 F. Hoffmann-La Roche Ag Interleukine 10 immunoconjugates
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
WO2017165464A1 (en) 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
WO2018005226A2 (en) 2016-06-22 2018-01-04 Alkermes, Inc. Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6428985B1 (en) * 1998-12-02 2002-08-06 The Regents Of The University Of Michigan Immunosuppressive structural definition of IL-10
US20130316404A1 (en) * 2010-11-26 2013-11-28 The University Of Manchester Covalently linked interleukin-10
US20130336925A1 (en) * 2012-06-08 2013-12-19 Alkermes, Inc. Fusion Polypeptides Comprising Mucin-Domain Polypeptide Linkers
WO2015017548A2 (en) * 2013-07-31 2015-02-05 Amgen Inc. Stabilization of fc-containing polypeptides
WO2016100788A1 (en) * 2014-12-19 2016-06-23 Alkermes, Inc. Single chain fc fusion proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
2016100788YOON, Sung Il, et al., Conformational changes mediate interleukin-10 receptor 2 (IL-10R2) binding to IL-10 and assembly of the signaling complex. J. Biol. Chem. 2006, vol. 281, No 46, pages 35088-35096 *

Also Published As

Publication number Publication date
CA3026393C (en) 2023-03-14
CA3026393A1 (en) 2018-01-04
JP2019527200A (ja) 2019-09-26
AU2017291321A1 (en) 2018-12-13
EP3474884A2 (en) 2019-05-01
JP7084881B2 (ja) 2022-06-15
NZ748787A (en) 2021-06-25
US20170368144A1 (en) 2017-12-28
US20190336582A1 (en) 2019-11-07
US10335459B2 (en) 2019-07-02
AU2020204457A1 (en) 2020-07-23
WO2018005226A2 (en) 2018-01-04
WO2018005226A3 (en) 2018-04-05
EP3474884A4 (en) 2020-08-19
US11534480B2 (en) 2022-12-27

Similar Documents

Publication Publication Date Title
US11534480B2 (en) Compositions and methods for modulating IL-10 immunostimulatory and anti-inflammatory properties
AU2018247255B2 (en) Single chain fc fusion proteins
DK2604693T3 (en) Single-chain TNFSF molecules
JP2024026738A (ja) 免疫調節融合タンパク質
US8338569B2 (en) FGFR extracellular domain acidic region muteins
WO2020252418A2 (en) Novel interleukin-2 variants for the treatment of cancer
CN108948207A (zh) 一种人白细胞介素10-Fc融合蛋白及其编码基因与应用
JP2023096044A (ja) 免疫調節融合タンパク質
NZ748787B2 (en) Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
EP4359429A1 (en) Interleukin 15 variants
US20240252601A1 (en) Ace2 fusion proteins and uses thereof
CN117597356A (zh) 基于白细胞介素-15的免疫细胞因子
HK1242337B (en) Single chain fc fusion proteins

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired